C12N 2770/36011
Togaviridae
C12N2770/36011 (Togaviridae) appears on 632 US grants and 920 published applications in this corpus.
Search patents in C12N- Granted patents
- 632
- Published applications
- 920
- Assignees
- 393
- Inventors
- 1,410
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 2 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 3 | 0 |
| 1992 | 4 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 3 | 0 |
| 1996 | 8 | 0 |
| 1997 | 3 | 0 |
| 1998 | 20 | 0 |
| 1999 | 10 | 0 |
| 2000 | 15 | 0 |
| 2001 | 19 | 2 |
| 2002 | 17 | 17 |
| 2003 | 18 | 33 |
| 2004 | 12 | 26 |
| 2005 | 4 | 19 |
| 2006 | 12 | 22 |
| 2007 | 10 | 23 |
| 2008 | 15 | 26 |
| 2009 | 13 | 22 |
| 2010 | 15 | 31 |
| 2011 | 14 | 36 |
| 2012 | 17 | 21 |
| 2013 | 20 | 29 |
| 2014 | 18 | 38 |
| 2015 | 15 | 26 |
| 2016 | 20 | 30 |
| 2017 | 22 | 32 |
| 2018 | 24 | 26 |
| 2019 | 26 | 38 |
| 2020 | 22 | 56 |
| 2021 | 33 | 46 |
| 2022 | 40 | 78 |
| 2023 | 64 | 82 |
| 2024 | 40 | 71 |
| 2025 | 30 | 57 |
| 2026 | 20 | 33 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/36111AlphavirusIndexing code545
- C12N 2770/36211RubivirusIndexing code66
- C12N 2770/36022New viral proteins or individual genes, new structural or functional aspects ofIndexing code14
- C12N 2770/36034Use of virus or viral component as vaccineIndexing code10
- C12N 2770/36021Viruses as suchIndexing code4
- C12N 2770/36051Methods of production or purification of viral materialIndexing code4
- C12N 2770/36061Methods of inactivation or attenuationIndexing code4
- C12N 2770/36032Use of virus as therapeutic agent, other than vaccineIndexing code2
All 14 subgroupsShow fewer
- C12N 2770/36071Demonstrated in vivo effectIndexing code1
- C12N 2770/36023Virus like particles [vlp]Indexing code0
- C12N 2770/36031Uses of virus other than therapeutic or vaccineIndexing code0
- C12N 2770/36033Use of viral protein as therapeutic agent other than vaccineIndexing code0
- C12N 2770/36041Use of virus, viral particle or viral elements as a vectorIndexing code0
- C12N 2770/36088For redistributionIndexing code0
Recent patents
- Cytokine immunotherapy22 Sep 2026US 12,742,182 B2VLP Therapeutics, LLC
- Prostate neoantigens and their uses28 Jul 2026US 12,692,513 B2Janssen Biotech, Inc.
- Alphavirus neoantigen vectors and interferon inhibitors16 Jun 2026US 12,653,883 B2Seattle Project Corp.
- Human monoclonal antibodies to Venezuelan equine encephalitis virus and uses therefor2 Jun 2026US 12,642,847 B2Vanderbilt University
- Galectin-targeting immunotherapy26 May 2026US 12,636,341 B2VLP Therapeutics, LLC
- Vaccine Adjuvants8 Oct 2026US 2026/0306623 A1Seqirus Inc.
- Dna vaccine for fish against salmonid alphavirus27 Aug 2026US 2026/0248901 A1Intervet Inc.
- Treatment of atopic dermatitis using self-replicating rna expressing il-3120 Aug 2026US 2026/0240967 A1Ceva Sante Animale
- Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp320 Aug 2026US 2026/0240977 A1Valneva SE
- Nanobiosensor and preparation method thereof and virus antibody detection method using same13 Aug 2026US 2026/0235602 A1National Defense Medical University
Most cited
By later US patents
- Eukaryotic layered vector initiation systems204US 5,814,482 A1998
- Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes185US 5,316,931 ABiosource Genetics Corporation · 1994
- Alphavirus vector constructs167US 5,843,723 AChiron Corporation · 1998
- Alphavirus structural protein expression cassettes152US 5,789,245 AChiron Corporation · 1998
- Eukaryotic layered vector initiation systems126US 6,015,686 AChiron Viagene, Inc. · 2000